How should PANS/PANDAS be evaluated and managed in a 10-year-old female with worsening obsessive‑compulsive symptoms?

Management of PANS/PANDAS with Worsening OCD in a 10-Year-Old Female

Treat this patient's worsening OCD symptoms with standard evidence-based psychiatric care (cognitive-behavioral therapy with exposure and response prevention plus selective serotonin reuptake inhibitors), while avoiding routine streptococcal testing, long-term antibiotic prophylaxis, and immunomodulatory therapies, as PANS/PANDAS remains an unproven hypothesis without established causal relationship to infections. 1

Primary Recommendation Based on Guideline Evidence

The American Heart Association's scientific statement explicitly states that PANDAS should be considered "only as a yet-unproven hypothesis" and provides Class III recommendations (meaning potentially harmful) against:

• Routine laboratory testing for group A streptococcus to diagnose PANDAS
• Long-term antistreptococcal prophylaxis to prevent exacerbations
• Immunoregulatory therapy (intravenous immunoglobulin, plasma exchange) to treat exacerbations 1

This represents the highest-quality guideline evidence available, endorsed by the American Academy of Pediatrics, and should guide your clinical approach.

Clinical Approach to This Patient

Immediate Psychiatric Management

Focus on treating the OCD symptoms themselves rather than pursuing a PANS/PANDAS diagnosis:

• Initiate cognitive-behavioral therapy with exposure and response prevention (ERP), which remains the gold standard for pediatric OCD 2
• Consider SSRI therapy (fluoxetine is well-studied in pediatric OCD) if symptoms are severe or functionally impairing 3
• Assess for acute safety concerns including suicidality, self-injurious behaviors, and functional decline that may require higher levels of care 4

Diagnostic Evaluation

Rather than testing for streptococcal infection, perform a thorough differential diagnosis to exclude other treatable causes:

Rule out these specific conditions that can present with acute-onset OCD symptoms 5:

• Autoimmune encephalitis (anti-NMDAR, anti-GABAAR, anti-D2R)
• Systemic lupus erythematosus
• CNS infections (mycoplasma, herpes simplex, varicella zoster)
• Wilson disease (especially in this age group)
• Thyroid disorders
• Medication/drug effects
• Functional neurological disorder

Key clinical features to document:

• Exact timeline of symptom onset (truly abrupt vs. gradual)
• Temporal relationship to any documented infections
• Presence of concomitant symptoms: separation anxiety, irritability, emotional lability, behavioral regression, food restriction, urinary symptoms, sleep disturbance 6, 7
• Neurological examination findings, particularly for chorea or other movement disorders 5

Understanding the Controversy

Why Guidelines Recommend Against PANS/PANDAS-Specific Treatment

The 2009 AHA guideline's strong stance reflects fundamental problems with the PANS/PANDAS construct:

1. No established causal relationship between streptococcal infections and neuropsychiatric symptoms despite decades of research 1
2. Lack of validated biomarkers - elevated anti-streptolysin O or anti-DNAse B titers do not establish causation and are common in healthy children 2
3. Heterogeneous clinical presentations that overlap substantially with standard pediatric OCD 6
4. Absence of high-quality treatment trials demonstrating benefit of infection-focused interventions 8

Recent Literature Context

While more recent research (2021-2026) continues to describe PANS/PANDAS cases and propose diagnostic protocols 8, 4, 2, 9, 6, none of this research has overturned the fundamental guideline recommendation. The 2025 Sydenham chorea consensus explicitly identifies "further exploration of the relation between neuropsychiatric symptoms in SC and the concept of PANS/PANDAS" as an area of need, confirming this remains unresolved 5.

When to Consider Alternative Approaches

If standard psychiatric treatment fails after adequate trials (8-12 weeks of appropriate SSRI dosing plus intensive CBT/ERP), then:

1. Reassess the diagnosis - consider the differential diagnoses listed above more aggressively
2. Consult pediatric neurology if movement disorders, seizures, or other neurological signs emerge
3. Consider neuropsychological testing to identify specific cognitive deficits that may guide intervention 6

Only in cases with documented acute rheumatic fever or Sydenham chorea should antibiotic prophylaxis be considered, following established rheumatic fever protocols 5

Critical Pitfalls to Avoid

• Do not delay effective psychiatric treatment while pursuing infectious workup or waiting for "medical stabilization" 10
• Do not interpret elevated streptococcal titers as diagnostic - these are common in school-age children and do not establish causation 2
• Do not pursue expensive immunomodulatory therapies (IVIG, plasmapheresis) outside of research protocols, as evidence does not support their use and they carry significant risks 1
• Do not prescribe long-term antibiotics as prophylaxis, which promotes resistance without proven benefit 1

Practical Management Algorithm

Week 1-2:

• Complete psychiatric evaluation and safety assessment
• Basic laboratory screening (CBC, CMP, TSH, consider Wilson disease screening if age-appropriate)
• Initiate or intensify CBT/ERP
• Consider SSRI if moderate-to-severe symptoms

Week 4-8:

• Reassess symptom trajectory
• If improving: continue current management
• If worsening or no response: consider consultation with pediatric neurology for expanded differential

Week 12+:

• If treatment-resistant despite adequate trials: comprehensive neurological evaluation including MRI brain, EEG, autoimmune encephalitis panel, and neuropsychological testing

Throughout: Provide family education that recovery may be gradual (months, not weeks) even with appropriate treatment 4, and that psychotherapy specifically targeting OCD symptoms shows the strongest evidence for benefit 2